期刊文献+

2-氨基-5-溴-3-吗啉-4-基吡嗪的合成

Synthesis of 2-Amino-5-bromo-3-morpholin-4-ylpyrazine
下载PDF
导出
摘要 以2-氨基吡嗪(Ⅰ)为原料,经溴代、吗啉取代,合成得到目标化合物2-氨基-5-溴-3-吗啉-4-基吡嗪(Ⅲ),合成路线总收率为45.9%(以2-氨基吡嗪计),目标化合物结构经1HNMR确证。该文对反应投料比、温度、反应时间等因素进行了考察并优化,最优反应条件为:n(2-氨基吡嗪)∶n(溴素)∶n(吡啶)=1∶2.1∶2.1,避光,40℃下反应30 min;每克3,5-二溴-2-氨基吡嗪加入4 mL吗啉,80℃下反应1 h。优化后的合成路线反应条件温和、操作简单、成本低廉,适合较大规模制备。 2-Amino-5-bromo-3-morpholin-4-ylpyrazine was prepared from 2-amidopyrazine in an overall yield of 45.9% via bromination and substitution by morpholine, and its structure was confirmed by ^1HNMR. The reaction conditions were optimized in terms of temperature, reactant proportions, and reaction time. The optimized reaction conditions are as follows : n ( 2-amidopyrazine ) : n ( bromine ) : n (pyridine) = 1:2. 1:2. 1, the reaction being conducted at 40 ~C for 30 rain,and kept in dark place;4 rnL morpholine was added per gram of 3,5-dibromopyrazin-2-amine, the reaction being conducted at 80℃ for an hour. The improved process has the advantages of mild reaction conditions, simple operation, and low cost, which is also suitable for large scale synthesis.
出处 《精细化工》 EI CAS CSCD 北大核心 2014年第8期988-990,1028,共4页 Fine Chemicals
基金 江西省教育厅科技计划项目(GJJ13578) 江西省大学生科研立项(20130702026)~~
关键词 2-氨基吡嗪 2-氨基-5-溴-3-吗啉-4-基吡嗪 工艺优化 医药与日化原料 2-amidopyrazine 2-amino-5-bromo-3-morpholin_4_ylpyrazine process optimization drug and cosmetic materials
  • 相关文献

参考文献10

  • 1Zhu W,Zhai X,Fu Q,et al. Desigal,synthesis and anticancer activity of 4-morpholinothieno [ 3,2-d ] pyrimidine derivatives beating arylmethylene hydrazine moiety [ J ]. Chemical & Pharmaceutical Bulletin ,2012,60 ( 8 ) : 1037 - 1045.
  • 2Mortensen D S, Perrin-Ninkovic S M, Harris R, et al. Discovery and SAR exploration of a novel series of imidazo [ 4,5-b ] pyrazin-2- ones as potent and selective mTOR kinase inhibitors [ J ]. Bioorganic & Medicinal Chemistry Letters ,2011,21 (22) :6793 - 6799.
  • 3Mielcke T R, Mascarello A, Filippi -Chiela E, et al. Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation [J]. European Journal of Medicinal Chemistry ,2012, 48 :255 - 264.
  • 4Martinez Gonzalez S,Hemandez A I, Varela C ,et al. Imidazo] 1,2- a J pyrazines as novel P13 K inhibitors [J] . Bioorganic & Medicinal Chemistry Letters,2012 ,22 (5) : 1874 -1878.
  • 5Wu P, Su Y , Liu X, et al. Synthesis and biological evaluation of novel 2-arylamino-3-( arylsulfonyl) quinoxalines as P13Ka inhibitors [J]. European Journal of Medicinal Chemistry, 2011 ,46 (11 ) :5540 - 5548.
  • 6Martinez Gonzalez S, Hernandez A I, Varela C, et al. Identification of ETP46321,a potent and orally bioavailable P13K a,1) inhibitor [J]. Bioorganic & Medicinal Chemistry Letters, 2012, 22 (10): 3460 -3466.
  • 7Crew A P, Bhagwat S V, Dong H, et al. Imidazo [I ,5 -a J pyrazines , orally efficacious inhibitors of mTORCl and mTORC2 [J] . Bioorganic & Medicinal Chemistry Letters, 2011,21 (7) : 2092 - 2097.
  • 8Wu P,Su Y,Liu X,et al. Discovery of noveI2-piperidinol-3- ( arylsulfonyl) quinoxalines as phosphoinositide 3 -kinase a (P13Ka) inhibitors [J] . Bioorganic & Medicinal Chemistry ,2012, 20(9) :2837 -2844.
  • 9Leahy J W , Buhr C A .Johnson H W B ,et al. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase inhibitors [J]. Journal of Medicinal Chemistry, 2012,55 ( II ) : 5467 -5482.
  • 10Murphy S T, Alton G, Bailey S, et al. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDKI ) [J]. Journal of Medicinal Chemistry, 2011 ,54 ( 24 ) : 8490 -8500.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部